中华放射肿瘤学杂志
Saturday, Apr. 5, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2016, Vol. 25 Issue (8): 807-812    DOI: 10.3760/cma.j.issn.1004-4221.2016.08.004
Thoracic Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Prospective non-randomized clinical study of biomarker-guided concurrent chemoradiotherapy for unrescetable esophageal squamous cell carcinoma
Yang Zhe,Dai Honghai,Feng Alei,Li Qiang,Lyu Dongxiao,Han Junqing
Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong University,Ji’nan 250021,China
Download: PDF (942 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Objective To evaluated the efficacy of biomarker-guided concurrent chemoradiotherapy in unrescetable esophageal squamous cell carcinoma patients. Methods 54 cases of unrescetable esophageal squamous cell carcinoma were enrolled in the prospective non-randomized clinical study and divided into study group and control group. All cases were treated with concurrent chemoraditherapy. Intensity-modulated radiation therapy was used with a dose of 60-66 Gy. Chemotherapy was perfromed on day 1 and d29.In the study group the selection of the chemotherapy drug was based on the excision repair cross-complementation 1(ERCC1),thymidylate synthetase (TYMS),ribonucleotide reductase M1(RRM1),and the β-tubulin isotype Ⅲ(TUBB3) mRNA expression levels. In the control group,the regiment for chemotherapy was Cisplatin plus Fluorouracil. TheObjective response rate and overall survival (OS) were calculated using Kaplan-meier method and log-rank test was used for between-group comparison. The survival rate was calculated using Kaplan-Meier method and analyzed using log-rank method,other comparison was performed by χ2 test. Results The follow-up rate was 100% in the study group and 96% in the controll group. The Objective response rate of the study group and the control group were 85% and 86(P=0.483),respectively. The median survival time (MST) in the study group was 35.5 months and that in the control group was 25.8 months. The 1-,2-,and 3-year OS rates of the study group and the control group were 84%,68%,46% and 71%,59%,28% respectively (P=0.047).No significant differences were observed in the incidence of side-effects in the two groups. Conclusions Selecting the chemotherapy drug according to biomarker,combined with radiation therapy,could improve survival.in unrescetable esophageal squamous cell carcinoma. The value needs further investigation.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Yang Zhe
Dai Honghai
Feng Alei
Li Qiang
Lyu Dongxiao
Han Junqing
Key wordsEsophageal neoplasms/radiochemotherapy      Radiochemotherapy      concurrent      Biomarker      Prognosis     
    
Corresponding Authors: Han Junqing,Email:hanjunqing1960@126.com     E-mail: hanjunqing1960@126.com
Cite this article:   
Yang Zhe,Dai Honghai,Feng Alei et al. Prospective non-randomized clinical study of biomarker-guided concurrent chemoradiotherapy for unrescetable esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(8): 807-812.
Yang Zhe,Dai Honghai,Feng Alei et al. Prospective non-randomized clinical study of biomarker-guided concurrent chemoradiotherapy for unrescetable esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(8): 807-812.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2016.08.004     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2016/V25/I8/807
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn